Pfizer Inc. $PFE Shares Sold by Keystone Financial Planning Inc.

Keystone Financial Planning Inc. cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 254,855 shares of the biopharmaceutical company’s stock after selling 1,332 shares during the quarter. Pfizer accounts for approximately 1.9% of Keystone Financial Planning Inc.’s holdings, making the stock its 13th biggest position. Keystone Financial Planning Inc.’s holdings in Pfizer were worth $6,178,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. Sage Mountain Advisors LLC boosted its stake in Pfizer by 47.3% in the 2nd quarter. Sage Mountain Advisors LLC now owns 22,789 shares of the biopharmaceutical company’s stock worth $552,000 after buying an additional 7,322 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in Pfizer by 18.8% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 15,601,116 shares of the biopharmaceutical company’s stock worth $378,171,000 after purchasing an additional 2,466,969 shares during the last quarter. West Michigan Advisors LLC increased its holdings in shares of Pfizer by 15.5% in the 2nd quarter. West Michigan Advisors LLC now owns 11,046 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 1,482 shares during the last quarter. Moloney Securities Asset Management LLC boosted its position in Pfizer by 3.4% during the 2nd quarter. Moloney Securities Asset Management LLC now owns 74,045 shares of the biopharmaceutical company’s stock valued at $1,795,000 after purchasing an additional 2,445 shares during the period. Finally, Jackson Hole Capital Partners LLC boosted its position in Pfizer by 13.5% during the 2nd quarter. Jackson Hole Capital Partners LLC now owns 125,819 shares of the biopharmaceutical company’s stock worth $3,050,000 after acquiring an additional 14,982 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.5%

NYSE:PFE opened at $24.79 on Friday. The stock’s fifty day moving average price is $24.87 and its two-hundred day moving average price is $24.17. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market cap of $140.92 billion, a price-to-earnings ratio of 13.18, a P/E/G ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.17.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the prior year, the company earned $0.60 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is presently 91.49%.

Analyst Ratings Changes

Several brokerages have recently weighed in on PFE. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley cut their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Bank of America lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $28.13.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.